Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 876, Issue 2, 2008, Pages 277-282

  Zhang, Wenjiang ^a   Seymour, Lesley ^b   Chen, Eric X ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Institut national du cancer du Canada   (Canada)

Author keywords

HPLC; Mass spectrometry; Oxaliplatin

Indexed keywords

ACETONITRILE; CHROMATOGRAPHIC ANALYSIS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; IONIZATION OF LIQUIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY; PHASE SEPARATION; PLASMA (HUMAN); PLASMAS; SPECTROMETERS; SPECTROMETRY; SPECTRUM ANALYSIS;

CARBOPLATIN; CLINICAL STUDIES; HPLC; HUMAN PLASMAS; INTERNAL STANDARDS; IONIZATION MODES; LINEAR RANGES; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRIES; LOWER LIMIT OF QUANTITATIONS; OXALIPLATIN; RELATIVE STANDARD DEVIATIONS; REVERSE PHASE COLUMNS; TANDEM MASS SPECTROMETRIES; TURBO ION SPRAYS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CARBOPLATIN; OXALIPLATIN;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IONIZATION; MASS SPECTROMETER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; ORGANOPLATINUM COMPOUNDS; PLASMA; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION;

EID: 56549099462     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.10.055     Document Type: Article

References (10)

1. de G.A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le B.N., Louvet C., Hendler D., de B.F., Wilson C., Morvan F., and Bonetti A. J. Clin. Oncol. 18 (2000 2938)
2. Rothenberg M.L., Oza A.M., Bigelow R.H., Berlin J.D., Marshall J.L., Ramanathan R.K., Hart L.L., Gupta S., Garay C.A., Burger B.G., Le B.N., and Haller D.G. J. Clin. Oncol. 21 (2003 2059)
3. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C., and Alberts S.R. J. Clin. Oncol. 22 (2004) 23
4. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., and Gamelin E. Clin. Cancer Res. 6 (2000) 1205
5. Kloft C., Appelius H., Siegert W., Schunack W., and Jaehde U. Ther. Drug Monit. 21 (1999) 631
6. Morrison J.G., White P., McDougall S., Firth J.W., Woolfrey S.G., Graham M.A., and Greenslade D. J. Pharm. Biomed. Anal. 24 (2000) 1
7. Kern W., Braess J., Bottger B., Kaufmann C.C., Hiddemann W., and Schleyer E. Clin. Cancer. Res. 5 (1999) 761
8. Ehrsson H., and Wallin I. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 795 (2003) 291
9. Food and Drug Administration, Department of Health and Human Services. Guidance for Industry: Bioanalytical Method Validation (2001). http://www.fda.gov/cder/Guidance/4252fnl.pdf http://www.fda.gov/cder/Guidance/4252fnl.pdf
10. Ehrsson H., Wallin I., and Yachnin J. Med. Oncol. 19 (2002) 261